To include your compound in the COVID-19 Resource Center, submit it here.

Humira adalimumab: Phase III data

A 24-week, double-blind, international Phase III trial in 420 patients showed that once-monthly 80 mg Humira missed the co-primary endpoint of a significantly greater number of

Read the full 264 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE